Literature DB >> 12445627

Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation.

Makoto Sugawa1, Yoko Sakurai, Yasuko Ishikawa-Ieda, Hiroshi Suzuki, Hiroaki Asou.   

Abstract

We investigated the effects of erythropoietin (Epo) in glial cell development, especially the maturation of late stage immature oligodendrocytes and the proliferation of astrocytes. Epo mRNA level in oligodendrocytes was much more prominent than those in neurons or astrocytes, which were the same as those in the young adult kidney, while Epo receptor (Epo-R) mRNA level were almost the same among neural cells, kidney and liver tissues. On immunohistochemical examination, Epo-R expression was also detected in O4-positive immature oligodendrocytes and glial fibrillary acidic protein positive astrocytes. These results suggested that types of both glial cells are responsive to Epo. The numbers of mature oligodendrocytes, which are characterized by myelin basic protein and process development, were increased by treatment with recombinant human Epo (rhEpo) (0.001-0.1 U/ml). The maturation of oligodendrocytes was also enhanced by coculture with astrocytes in vitro. However, when mixed cultured cells (oligodendrocytes+astrocytes) were treated with anti-Epo antibody and/or soluble Epo-R, the differentiation of oligodendrocytes was partially inhibited. Interestingly, high dose rhEpo (1, 3, 10 U/ml) markedly enhanced the proliferation of astrocytes. These results suggested that Epo not only promotes the differentiation and/or maturation in oligodendrocytes, but also enhances the proliferation of astrocytes. It is generally accepted that astrocytes produce Epo, and therefore Epo might act on astrocytes in an autocrine manner. The astrocytes stimulated with Epo may further accelerate the maturation of oligodendrocytes. These comprehensive effects of Epo might also affect the ability of oligodendrocyte lineage cells to promote myelin repair in the normal and damaged adult central nervous system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445627     DOI: 10.1016/s0168-0102(02)00161-x

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  58 in total

1.  Outcomes of extremely low birth weight infants given early high-dose erythropoietin.

Authors:  R M McAdams; R J McPherson; D E Mayock; S E Juul
Journal:  J Perinatol       Date:  2012-06-21       Impact factor: 2.521

Review 2.  Oligodendrocyte Development and Plasticity.

Authors:  Dwight E Bergles; William D Richardson
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-08-20       Impact factor: 10.005

3.  Erythropoietin: still on the neuroprotection road.

Authors:  Nelvys Subirós; Diana García Del Barco; Rosa M Coro-Antich
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

4.  Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors.

Authors:  M Kondyli; G Gatzounis; A Kyritsis; J Varakis; M Assimakopoulou
Journal:  J Neurooncol       Date:  2010-03-25       Impact factor: 4.130

5.  Use of Erythropoietin as adjuvant therapy in nerve reconstruction.

Authors:  J A Lohmeyer; E Essmann; S J Richerson; C Hagel; J T Egana; A Condurache; P Ganske; K Schulz; P Mailänder; H G Machens
Journal:  Langenbecks Arch Surg       Date:  2008-02-26       Impact factor: 3.445

6.  Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin.

Authors:  Robin K Ohls; Daniel C Cannon; John Phillips; Arvind Caprihan; Shrena Patel; Sarah Winter; Michael Steffen; Ronald A Yeo; Richard Campbell; Susan Wiedmeier; Shawna Baker; Sean Gonzales; Jean Lowe
Journal:  Pediatrics       Date:  2016-02-15       Impact factor: 7.124

7.  The Differential Effects of Erythropoietin Exposure to Oxidative Stress on Microglia and Astrocytes in vitro.

Authors:  Praneeti Pathipati; Donna M Ferriero
Journal:  Dev Neurosci       Date:  2017-05-17       Impact factor: 2.984

8.  Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo.

Authors:  Robin K Ohls; Beena D Kamath-Rayne; Robert D Christensen; Susan E Wiedmeier; Adam Rosenberg; Janell Fuller; Conra Backstrom Lacy; Mahshid Roohi; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Hannah Peceny; Daniel C Cannon; Jean R Lowe
Journal:  Pediatrics       Date:  2014-05-12       Impact factor: 7.124

Review 9.  Neonatal Encephalopathy: Update on Therapeutic Hypothermia and Other Novel Therapeutics.

Authors:  Ryan M McAdams; Sandra E Juul
Journal:  Clin Perinatol       Date:  2016-06-22       Impact factor: 3.430

10.  Erythropoietin as a neuroprotectant for neonatal brain injury: animal models.

Authors:  Christopher M Traudt; Sandra E Juul
Journal:  Methods Mol Biol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.